NEW ADVANCES IN THE TREATMENT OF BREAST CANCER: THE ROLE EPOTHILONES

The review considers information about the efficacy and safety of Ixabepilone as a monotherapy and as a component of combination therapy for advanced breast cancer. Successful treatment of metastatic breast cancer is often confounded by resistance to chemotherapy, in particular anthracyclines and taxanes. The limited number of effective treatment options for patients with more aggressive biological subtypes, such as triple-negative metastatic breast cancer, is especially important. A therapy clinically proven to be effective in this subtype would be of great value. Ixabepilone, a novel synthetic lactam analog of epothilone B, demonstrated better clinical outcomes in metastatic disease, particularly in triple-negative breast cancer and “intensivelytreated” variant. Most recently, studies have shown the activity of ixabepilone in the neoadjuvant setting, suggesting a role for this drug in primary disease.

1. Desantis C, Siegel R, Bandi P, and Jamal А. Breast cancer statistics 2011. CA: A Cancer Journal for Clinicians, 2011, 61(6): 408–418.

2. Семиглазов В.Ф., Палтуев Р.М., Семиглазова Т.Ю. и др. Опухоли репродуктивной системы. М.: Рекламно-издательская группа МегаПро, 2013. / Semiglazov VF, Paltuev RM, Semiglazova TY., et al. Tumors of reproductive system. M.: Advertising and Publishing Group MegaPro, 2013.

3. Семиглазов В.Ф., Семиглазов В.В., Криворотько П.В., Палтуев Р.М., Дашян Г.А., Семиглазова Т.Ю. Руководство по лечению рака молочной железы. 2016, 155с. / Semiglazov VF, Semiglazov VV, Krivorotko PV, Paltuev RM, Dashyan GA, Semiglazova TY. Guide to treatment of breast cancer. 2016, 155.

4. Семиглазов В.В., Жабина А.С., Осипов М.А., Котова З.С. Клименко В.В. и соавт. Качество жизни – принципиальный критерий эффективности таргетной терапии метастатического HER2-положительного рака молочной железы. Современная онкология, 2015, 17(1): 19-24./ Semiglazov VV, Zhabina AS, Osipov MA, Kotova Z.S., Klimenko V.V. Et al. Quality of life is a criterion of the effectiveness of targeted therapy for metastatic HER2-positive breast cancer. Modern Oncology, 2015, 17(1): 19-24.

5. Семиглазова Т.Ю., Гершанович М.Л. Пероральные фторпиримидины в химиотерапии злокачественных опухолей. Вопр. онкологии, 2001, 47(4): 388-394. / Semiglazova TY, Gershanovich ML. Peroral fluoropyrimidines in chemical therapy of malignant tumours. Vopr onkologii, 2001, 47(4): 388-394.

6. Семиглазова Т.Ю., Гершанович М.Л. Кселода (капецитабин) в лечении диссеминированного рака молочной железы после исчерпанного эффекта антрациклинов и таксанов. Вопр. онкологии, 2001, 47(3): 298-302./Semiglazova TY, Gershanovich ML. Xeloda (capecitabine) in therapy of disseminated mammary gland cancer after the exhausted effect of antracyclines and taxanes. Vopr onkologii, 2001, 47(3): 298- 302.

7. Semiglazova T, Gershanovich M. The efficacy of Capecitabine (Xeloda) in Antracyclin- refractory and Antracyclin and Docetaxel-refractory metastatic breast cancer (MBC). Proc Am Soc Clin Oncol, 2002, 21(2061): 164.

8. Семиглазова Т.Ю., Клюге В.А., Семиглазов В.В., Криворотько П.В., Дашян Г.А., Палтуев Р.М., Ткаченко Е.В., Донских Р.В., Семиглазов В.Ф. Новые возможности улучшения продолжительности и качества жизни: эрибулин в лечении больных диссеминированным раком молочной железы. Современная онкология, 2016, 18(2): 29-35./ Semiglazova TY, Klyuge VA, Semiglazov VV, Krivorotko PV, Dashyan GA, Paltuev RM, Tkachenko EV, Donskikh RV, Semiglazov VF. New possibilities for improving the duration and quality of life: Erybulin in the treatment of patients with disseminated breast cancer. Modern oncology, 2016, 18(2): 29-35.

9. Guarneriand V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist, 2009, 14(7): 645–656.

10. Perou CM, Sørile T, Eisen MB et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.

11. Fojo AT and Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Seminars in Oncology, 2005, 32(7): S3–S8.

12. Geney R, Ungureanu IM, Li D, and Ojima I. Overcoming multidrug resistance in taxane chemotherapy. Clinical Chemistry and Laboratory Medicine, 2002, 40(9): 918–925.

13. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annual Review of Medicine, 1997, 48: 353-374.

14. Hudis CA and Gianni L. Triple-negative breast cancer: an unmet medical need. The oncologist, 2011, 16 (1): 1–11.

15. Orr GA, Verdier-Pinard P, McDaid H, and Horwitz SB. Mechanisms of Taxol resistance related to microtubules, Oncogene, 2003, 22(47): 7280–7295.

16. Hari M, Yang H, Zeng C, Canizales M, and Cabral F. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motility and the Cytoskeleton, 2003, 56(1): 45–56.

17. Shalli K, Brown I, Heys SD and Schofield AC. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB Journal, 2005, 19(10): 1299–1301.

18. Tommasi S, Mangia A, Lacalamitaetal R. Cytoskeletonand paclitaxel sensitivity in breast cancer: the role of β-tubulins. International Journal of Cancer, 2007, 120(10): 2078-2085.

19. Alli E, Sharma VB, Sunderesakumar P, and Ford JM. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADPribose) polymerase. Cancer Research, 2009, 69(8): 3589-3596.

20. Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105(44): 17079-17084.

21. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 2005, 434(7035): 913-917.

22. Farmer H, McCabe H, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434(7035):917-921.

23. O’Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple- negative breast cancer. New England Journal of Medicine, 2011, 364(3): 205-214.

24. O’Shaughnessy J, Schwartzberg LS, Danso MA et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (G/C) in metastatic triplenegative breast cancer (TNBC). Journal of Clinical Oncology, 2011, 29(15s), abstract 1007.

25. Cortes J, O’Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open- label randomised study. The Lancet, 2011, 377(9769): 914-923.

26. Bode CJ, Gupta ML, Rei EA, Suprenant KA, Georg GI, and. Himes RH. Epothilone and paclitaxel: unexpect eddierences in promoting the assembly and stabilization of yeast microtubules. Biochemistry, 2002, 41(12): 3870-3874.

27. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule- stabilizing agents with a taxol-like mechanism of action. Cancer Research, 1995, 55(11): 2325- 2333.

28. Giannakakou P, Gussio R, Nogales E et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97(6): 2904–2909.

29. Chuang E, Wiener N, Christos P et al. Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Annals of Oncology, 2010, 21(10): 2075–2080.

30. Hunt JT. Discovery of Ixabepilone. Molecular Cancer Therapeutics, 2009, 8(2): 275–281.

31. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clinical Cancer Research, 2001, 7(5): 1429–1437.

32. Jordan M, Miller H, Ni L, et al. The Pat-21 breast cancer model derived from a patient with primary taxol resistance recapitulates the phenotype of its origin, has altered betatubulin expression and is sensitive to ixabepilone. in Proceedings of the American Association for Cancer Research Annual Meeting, 2006, abstract LB-280, Washington, DC, USA.

33. Perez EA, Patel T, and Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2- negative (triple-negative) breast cancer. Breast Cancer Research and Treatment, 2010, 121(2): 261–271.

34. Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemotherapy and Pharmacology, 2009, 63(2): 201–212.

35. Rivera E, Lee J, and Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solidtumors. Oncologist, 2008, 13(12): 1207–1223.

36. Goodin S, Kane MP, and Rubin EH. Epothilones: mechanism of action and biologic activity. Journal of Clinical Oncology, 2004, 22(10): 2015–2025.

37. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology, 2007, 25(23): 3407–3414.

38. Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology, 2010, 28(20): 3256–3263.

39. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology, 2007, 25(33): 5210–5217.

40. Jassem J, Fein L, Karwal M, et al. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast, 2012, 21(1): 89– 94.

41. Rugo HS, Campone M, Amadori D, et al. Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bevacizumab (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. Journal of Clinical Oncology, 2010, 28(15s): 1040.

42. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine, 2007, 357(26): 2666– 2676.

43. Smith JW, Vukelja SJ, Rabe AC et al. Final results of a phase II randomized trial of weekly or every-3-week ixabepilone in metastatic breast cancer (MBC). in Proceedings of the Breast Cancer Symposium, 2010, Abstract 268.

44. Moulder S, Li H, Wang M, et al. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Research and Treatment, 2010, 119(3): 663–671.

45. Awada A, Piccart MJ, Jones SF, et al. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemotherapy and Pharmacology, 2009, 63(3): 417–425.

46. Roch´e H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. Journal of Clinical Oncology, 2007, 25(23): 3415–3420.

47. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS- 247550), an epothilone B analog, in patients with taxaneresistant metastatic breast cancer. Journal of Clinical Oncology, 2007, 25(23): 3399–3406.

48. Plummer R, Woll P, Fyfeetal D. A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies. Clinical Cancer Research, 2008, 14(24): 8288–8294.

49. Tolaney SM, Najita J, Chen W, et al. A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. Cancer Research, 2009, 69, abstract 3137.

50. Baselga J, Zambetti M, Llombart-Cussac A. et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. Journal of Clinical Oncology, 2009, 27(4): 526–534.

51. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. Journal of Clinical Oncology, 2006, 24(13): 2019–2027.

52. Wardley A. Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer. Oncologist, 2006, 11(1): 20–26.

53. Wolmark N, Wang J, Mamounas E, Bryant J, and Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nineyear results from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of the National Cancer Institute Monographs, 2001, 30: 96–102.

54. Rosenberg KJ, Ross JL, Feinstein HE, Feinstein SC, and Israelachvili J. Complementary dimerization of microtubule-associated tau protein: implications for microtubule bundling and taumediated pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105(21): 7445–7450.

55. Felgner H, Frank R, Biernat J, et al. Domains of neuronal microtubule-associated proteins and flexural rigidity of microtubules. Journal of Cell Biology, 1997, 138(5): 1067– 1075.

56. Choi MC, Raviv U, Miller HP, et al. Human microtubule associated-protein tau regulates the number of protofilaments in microtubules: a synchrotron X-ray scattering study. Biophysical Journal, 2009, 97(2): 519–527.

57. Katherine H, Rak Tkaczuk. Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer. Breast Cancer: Basic and Clinical Research, 2011, 5: 1–14.

58. American Cancer Society. Cancer Facts &Figures 2016. Atlanta: American Cancer Society, 2016.